Literature DB >> 8126697

Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.

P S Portoghese1, M Sultana, S T Moe, A E Takemori.   

Abstract

Naltrindole (1) (NTI) is a highly potent and selective delta-opioid receptor antagonist. In an effort to understand the origin of the high potency, affinity, and selectivity of NTI, we have examined the conformational role of its indolic benzene moiety through the synthesis of related naltrexone derivatives 3-8, which contain the benzene moiety in different orientations and at different attachments in the molecule. One of these naltrexone derivatives, 5, whose 7-indanyl benzene moiety is orthogonal to ring C of the morphinan system, is a potent delta-opioid receptor antagonist in vitro and in vivo. Computer-assisted molecular overlay studies of the minimized structures (2-8) revealed the importance of the position of the benzene moiety for effective interaction with delta-opioid receptors. In compounds 2, 4, and 5, the aromatic ring falls in the same region of space as that of the indolic benzene moiety of NTI, and all of these ligands possessed significant activity at delta-opioid receptors. Analogues (3 and 6-8) which were shown to have relatively weak delta-opioid receptor antagonist potency have their aromatic groups located in a space that is different from that of the more potent analogues.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8126697     DOI: 10.1021/jm00031a006

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  A new group of highly active analgesic of the morphinan family.

Authors:  T G Tolstikova; E E Shultz; M P Dolgikh; G A Tolstikov
Journal:  Dokl Biol Sci       Date:  2004 Jan-Feb

2.  Quantitative conformationally sampled pharmacophore for delta opioid ligands: reevaluation of hydrophobic moieties essential for biological activity.

Authors:  Denzil Bernard; Andrew Coop; Alexander D MacKerell
Journal:  J Med Chem       Date:  2007-03-17       Impact factor: 7.446

3.  Docking studies suggest ligand-specific delta-opioid receptor conformations.

Authors:  Vuk Micovic; Milovan D Ivanovic; Ljiljana Dosen-Micovic
Journal:  J Mol Model       Date:  2008-12-04       Impact factor: 1.810

4.  Comparison of cyclic delta-opioid peptides with non-peptide delta-agonist spiroindanyloxymorphone (SIOM) using the message-address concept: a molecular modeling study.

Authors:  P Gao
Journal:  J Comput Aided Mol Des       Date:  1996-08       Impact factor: 3.686

5.  The mu- and delta-opioid pharmacophore conformations of cyclic beta-casomorphin analogues indicate docking of the Phe3 residue to different domains of the opioid receptors.

Authors:  W Brandt; M Stoldt; H Schinke
Journal:  J Comput Aided Mol Des       Date:  1996-06       Impact factor: 3.686

6.  A uniform molecular model of delta opioid agonist and antagonist pharmacophore conformations.

Authors:  W Brandt
Journal:  J Comput Aided Mol Des       Date:  1998-11       Impact factor: 3.686

7.  Synthesis and pharmacological activities of 6-glycine substituted 14-phenylpropoxymorphinans, a novel class of opioids with high opioid receptor affinities and antinociceptive potencies.

Authors:  Mariana Spetea; Petra Windisch; Yan Guo; Indre Bileviciute-Ljungar; Johannes Schütz; Muhammad Faheem Asim; Ilona P Berzetei-Gurske; Pal Riba; Kornel Kiraly; Susanna Fürst; Mahmoud Al-Khrasani; Helmut Schmidhammer
Journal:  J Med Chem       Date:  2011-01-14       Impact factor: 7.446

8.  Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects.

Authors:  Rakesh H Vekariya; Wei Lei; Abhisek Ray; Surendra K Saini; Sixue Zhang; Gabriella Molnar; Deborah Barlow; Kelly L Karlage; Edward J Bilsky; Karen L Houseknecht; Tally M Largent-Milnes; John M Streicher; Subramaniam Ananthan
Journal:  J Med Chem       Date:  2020-06-30       Impact factor: 8.039

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.